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Our knowledge and understanding of the tumormicroenvironment (TME) have been recently expandedwith the recognition of the
important role of innate lymphoid cells (ILC). Three different groups of ILC have been described based on their ability to produce
cytokines that mediate the interactions between innate and adaptive immune cells in a variety of immune responses in infection,
allergy, and autoimmunity. However, recent evidence from experimental models and clinical studies has demonstrated that ILC
contribute to the mechanisms that generate suppressive or tolerant environments that allow tumor regression or progression.
Defining the complex network of interactions and crosstalk of ILC with other immune cells and understanding the specific
contributions of each type of ILC leading to tumor development will allow themanipulation of their function and will be important
to develop new interventions and therapeutic strategies.
1. Introduction
Developments in both basic immunology and tumor biology
have increased our knowledge of the interactions between the
tumor cells and the immune system. Collectively referred to
as the tumor microenvironment (TME), cancers are complex
tissues that are comprised of malignant cells and a multitude
of stromal cells, such as fibroblasts, epithelial cells, and
innate and adaptive immune cells. The TME also includes
cells that form blood and lymphatic vasculature, as well as
specialized mesenchymal cell types that are unique to each
tissue microenvironment [1, 2]. Recently, innate lymphoid
cells (ILC) have been added to the list of immune cells that
may contribute to the TME [3]. Components within the TME
have been shown in experimental models and clinical studies
to provide either host protection leading to tumor regression
or tumor promotion by providing an immunosuppressive
milieu (Table 1). This review will focus primarily on current
views of the role of ILC on the control or induction of tumor
development and their crosstalk with other immune cells.
We also comment on different experimental approaches to
further investigate ILC function.
2. The Innate Lymphoid Cells (ILC) Family
Lacking a B cell or T cell receptor, ILC are derived from a
common lymphoid progenitor and possess a wide range of
cell surface markers, many of which have only recently been
elucidated [4, 5]. It has been suggested that these antigen
receptor-lacking cells play a key role in facilitating and coor-
dinating the innate and adaptive immune responses because
they are evolutionary precursors of the adaptive immune
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Table 1: Involvement of ILC in different types of tumors.The three different ILC groups have been linked andhave been shown to be associated
with pro- or antitumor activities in diverse types of tumors.Themechanisms involved include secretion of cytokines and induction of changes
in the tumor microenvironment that contribute to control of tumor growth or tumor progression and escape. For details, see main text.
ILC group Tumor type Effect Mechanism
ILC1 Intestinal tumors Antitumor Secretion of IFN-𝛾, activation of cytotoxic CD8
+ T cells, inhibition of
macrophage differentiation, and tumor angiogenesis
ILC2 Melanoma Antitumor Secretion of IL-5 and recruitment of eosinophils
ILC2 Breast cancer Protumor TGF-𝛽-mediated induction of MDSC and Treg
ILC2 Cholangiocarcinoma Protumor IL-13-mediated proliferation
ILC3 Colon cancer Protumor Induction of inflammation by secretion of IL-17 and IL-22
ILC3 Colon cancer Protumor IL-22-induced proliferation of tumor cells
ILC3 Melanoma Antitumor Increased expression of ICAM and VCAM in tumor vasculature allows CD4
+
and CD8+ infiltration
system [6]. ILC comprise a small population of mononuclear
hematopoietic cells that can be found in the circulation and
tissues. Recent moves to propose a uniform nomenclature
divide ILC into three subgroups based on the production of
Th1, Th2, and Th17 cell associated cytokines [6, 7]. This led
to an expert consortium recommending dividing ILC into
3 distinct categories (group 1, group 2, and group 3 ILC)
based on the expression of transcription factors, phenotypic
markers, and effector cytokine production profiles [6].
2.1. Group 1 ILC. Group 1 ILC (ILC1) have a wide range
of functions, including cytotoxicity, macrophage activation,
immunity to viruses and cancer, and chronic inflammation
[8]. ILC1 are dependent on the transcription factor T-bet
(encoded by the Tbx21 gene). There are 2 main subgroups of
group 1 ILC in human and mouse—natural killer (NK) cells
and non-NK ILC1—and their phenotypic markers and effec-
tor cytokines are well defined (Tables 2 and 3). NK cells and
non-NK ILC1 can be distinguished based on the expression of
the transcription factor Eomesodermin (Eomes); while NK
cells express it, non-NK ILC1 do not. [9]. Furthermore, NK
cells do not express IL-1 receptor (IL-1R) and therefore do
not require development of the transacting T cell-specific
transcription factor- (GATA-) 3, which is required by all
other ILC including the non-NK ILC1 [10]. Further, only
NK cells are distinguished by the expression of CD56 and
natural cytotoxicity receptors (NCRs), including NCR1 and
NCR2 (also known as NKp46 and NKp44, resp.) [11]. ILC1
produce a range of cytokines upon stimulation by IL-12 or IL-
18. Amongst the characteristic cytokines of group 1 ILC are
interferon gamma (IFN𝛾) and tumor necrosis factor (TNF-
𝛼), which are bothTh1-related cytokines [12].
2.2. Group 2 ILC. Group 2 ILC (ILC2) were first identified
in experiments with RAG-deficient mice, in which IL-25 or
IL-33 stimulation resulted in increased levels of IL-5 and
IL-13 [13], the key characteristic markers and cytokines for
the ILC2 (Tables 2 and 3). ILC2 are dependent on epithelial
cell-derived cytokines to coordinate responses during inflam-
mation and infection [14] and have an important role in
the antihelminth response [15] and development of allergy-
related inflammation [16, 17]. This group of ILC displays
little heterogeneity, with their development and maintenance
dependent on the transcription factors GATA-3 and retinoic
acid receptor-related orphan receptor-𝛼 (ROR𝛼), and the
growth factor independent 1 transcriptional repressor (Gfi-
1), respectively (reviewed in [18]). ILC2 are activated by IL-
25, IL-33, and the thymic stromal lymphopoietin (TSLP) and
play an important role in type 2 inflammation in the lung
and intestine due to their ability to affect T cell responses
to allergens through Th2-associated cytokines (IL-4, IL-5,
and IL-13) [19, 20]. ILC2 have also been found residing in
both human and murine skin. These skin ILC2 are “critically
dependent” on activation by TSLP, which is key to promoting
skin inflammation [21]. It is well known that the TNF
superfamily cytokine TL1A (TNFSF15) promotes ILC2 to
produce IL-13 ex vivo. Furthermore, TL1A costimulates the
expansion of ILC2 via their highly expressed TNF-receptor
superfamily member DR3 (TNFRSF25), independently of
the IL-25 or IL-33 stimulation pathways [22]. Studies with
DR3−/− mice demonstrated the importance of ILC2 stim-
ulation by TL1A at the mucosal barriers. The lack of this
costimulation leads to deregulated ILC2 functions, as these
mice developed gut helminth infections and were unable to
mount ILC2 responses in the lungs upon induction of an
allergic reaction by nasal papain challenge. The disruption
of ILC2 stimulation leads to reduced T cell accumulation
and response in T cell dependent allergic models, which
was suggested to be potentially beneficial for ILC2-related
allergies such as allergic asthma [23].
2.3. Group 3 ILC. Group 3 ILC are unique in that they
not only are involved in immunity against extracellular
bacteria and chronic inflammation but also play a key role in
intestinal homeostasis [24, 25] and lymphoid tissue develop-
ment. Indeed, one of the subgroups of ILC3-lymphoid tissue
inducer cells (LTi) was first discovered in the developing
lymph nodes, where they play a pivotal role in the formation
of lymphoid tissue during organogenesis [26].
In addition to LTi, group 3 ILC include NCR+ILC3 and
NCR−ILC3 (Table 2), which depend on GATA-3 and ROR𝛾t
expression. Unlike ILC2, which require ROR𝛾t for their
development only, ILC3 require ROR𝛾t for both development
and function, while GATA-3 regulates NCR+ILC3 as well as
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Table 2: Cell markers that define human and mouse ILC.
Marker
ILC1 ILC2 ILC3
NK cells Noncytotoxic ILC1 LTi NCR−ILC3 NCR+ILC3
H M H M H M H M H M H M
CD4∗1 − − − − − − − +/− − Low − −
CD11c − − − − − − − − − − − −
CD25 −/+ −/+ Low Low Low Low ND ND + + Low Low
CD56 + + − − ND ND − − − − −/+ −/+
CD117 − − − − + −/+ High High + + Low Low
CD127 (IL-7R𝛼) −/+ −/+ − − + + + + + + + +
NKp44 (NCR2)∗2 −/+ − − − − − − − − − + −
ICOS Low Low + + + + + + + + + +
NKp46 (NCR1) + + − − − − − − − − + +
CRTH2 (CD294) − − − − + + − − − − − −
IL-1R − − + + + + + + + + + +
IL-23R − − − − ND ND + + + + + +
IL-12R𝛽2 + + + + − − − − − − − −
ST2 − − − − + + − − − − − −
IL-17RB − − − − + + − − − − − −
NK1.1 (CD161) −/+ + −/+ − + − −/+ − ND − + −/+
Sca1 (Ly6A)∗3 − + − ND − + − − − + − ND
MHC class II − − − − − − + + + + − −
CCR6∗4 ND ND + − −/+ − + + + − + −
∗1There are differences between human and murine CD4 expression. Some murine LTi and a small number of NCR−ILC3 express CD4, whereas all human
subsets are negative. ∗2NKp44 is only expressed in human cells. ∗3Sca1 (also known as Ly6A) is a mouse cell surface protein of the Ly6 family and is not found
in human ILC. ∗4CCR6 expression in human and mouse ILC is different. In mice, CCR6 is not expressed in non-NK ILC1, ILC2, or NCR+ILC3. In humans,
ILC1, ILC2, and NCR+ILC3 all express CCR6. CCR6, C-C chemokine receptor type 6; CRTH2, chemoattractant receptor-homologous molecule expressed on
Th2 cells; ICOS, inducible T cell costimulator; IL, interleukin; ILC, innate lymphoid cell; LTi, lymphoid tissue inducer cells; MHC, major histocompatibility
complex; NCR, natural cytotoxicity triggering receptor; ND, not determined; NK, natural killer; Sca1, stem cell antigen 1; H, human; M, mouse.
Table 3: Effector cytokines produced by ILC.
Cytokines ILC1 ILC2 ILC3
NK cells Noncytotoxic ILC1 LTi NCR−ILC3 NCR+ILC3
IFN𝛾 + + − − + −
TNF + + − − + +
Perforin + − − − − −
Granzyme + − − − − −
IL-4 − − −/+ − − −
IL-5 − − + − − −
IL-9 − − + − − −
IL-13 − − + − − −
IL-17A − − − + + −
IL-22 − − − + + +
Areg − − + − − −
LT-𝛼1𝛽2 − − − + + +
GM-CSF + − − + + +
Areg, amphiregulin; GM-CSF, granulocyte macrophage colony-stimulating factor; INF𝛾, interferon gamma; LT, lymphotoxin; and TNF, tumor necrosis factor.
NK cells and plays a critical role in the production of IL-22
by these cells [6, 27, 28]. NCR+ILC3 express the activating
NKp46 orNKp44 receptors [11], and there is also a differential
expression of chemokine receptors, whereby only LTi but not
NCR+ILC3 express CCR6. Upon IL-23 or IL-1𝛽 stimulation
all ILC3 produce IL-22 (Table 3). IL-22 is highly important for
ILC3 functions, and studies have shown that mice deficient
in lymphotoxin- (LT-) 𝛼1𝛽2 were unable to produce IL-22 in
response to colonic infection [29]. In addition to IL-22, LTi
and NCR−ILC3 also produce the Th17 associated cytokine
IL-17 and granulocyte macrophage colony-stimulating fac-
tor (GM-CSF) which contribute to the proinflammatory
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response [30, 31]. Studies in models of intestinal infection
have shown that NCR−ILC3 are able to produce IFN-𝛾 in
addition to IL-22 and IL-17 [25]. Interestingly, it was noted
that the ability of ILC3 to produce IFN-𝛾 is coupled with the
disappearance of ROR𝛾t expression and increased expression
of T-bet [32]. Other studies have shown that T-bet expression
has the ability to induce a phenotype in ILC3 characterized
by high levels of IFN-𝛾 but not IL-17 [33]. These studies
suggest a degree of plasticity between ILC1 and ILC3, similar
to that described between Th1 and Th17 cells (reviewed in
[6]). This reported plasticity and ability to modify functional
phenotype might be important to explain the different effects
(pro- or antitumor) of ILC in different models of cancer as
will be discussed next.
3. Migration and Tissue Distribution of ILC
ILC display a tissue specific distribution with ILC2 and
NCR−ILC3 preferentially being distributed in skin, while
NCR+ILC3 are more prominent in the thymus, tonsils, bone
marrow, and gut (reviewed in [7]). The mechanism by which
the different types of ILC migrate to different tissues is
under the control of a differential expression of integrins
and chemokine receptors gradients similar to that described
for adaptive T cells [2]. Kim et al. have recently shown that
ILC1 and ILC3 migrate from the bone marrow to mesenteric
lymph nodes in a process controlled by the expression of
their homing receptor CCR7. Once in the lymph nodes,
ILC1 and ILC3 undergo a homing receptor program switch
and express CCR9 and 𝛼4𝛽7 receptors following stimulation
by retinoic acid (RA) produced by dendritic cells (DC).
This change in their receptor profile then allows migration
to intestinal tissue. ILC2 migration, on the other hand, is
developmentally controlled as the expression of gut homing
receptors occurs in the bone marrow [34]. Further evidence
has shown that expression of CXCR6 enables the definition
of subpopulations of ILC3 and dictates the distribution of
these cells within gut microenvironments. In a model of
intestinal infection, CXCL16 released by DC induces the
migration of ILC3 to the villus lamina propria where they
respond to IL-23 and produce IL-22, which is essential for the
release of antimicrobial peptides and infection control [35].
Recent studies using in vivo photoconversion to enable cell
tracking have also revealed how ILCmove frommucosal and
peripheral tissues to local draining lymphoid tissues.Mackley
et al. have shown that mouse ROR𝛾t+ILC migrate from
the intestine to draining mesenteric lymph nodes under the
influence of chemokine receptor CCR7 [36]. In this way, ILC
are enriched in locations such as the marginal sinus, bridging
channels, and interfollicular areas where they can interact
with trafficking lymphocytes as they recirculate through the
blood and lymphatic vessels [37, 38]. Given their anatomical
location and ability to rapidly secrete immunoregulatory
cytokines and crosstalk with other innate and adaptive
immune cells, ILC are proving to be crucial in the regulation
of immune responses. ILC respond to environmental stress in
immune disorders, infections, allergy, and autoimmunity by
producing cytokines that target stromal and epithelial cells,
which then mediate the communication between ILC and
other immune cells [39]. Understanding themechanisms and
molecules that inhibit [40, 41] or enhance ILC function is
vital for the development of immunotherapy for a number of
inflammatory diseases, including cancers [42, 43]. In the next
sections we will discuss evidence describing the role of ILC in
tumor biology.
4. Effector Mechanisms of ILC in Cancer
4.1. ILC1. The role of NK cells in cancer has been extensively
discussed in recent reviews [44] and here we will only
focus on non-NK ILC1. New insights from clinical and in
vivo studies have shown that non-NK ILC1, together with
adaptive immune cells, might be involved in responses that
either mediate the elimination of tumors (natural cytotoxi-
city, antibody-dependent cytotoxicity, and phagocytosis) or
promote tumor growth and metastasis (Figure 1) [15, 45–47].
Recent reports have started to unravel the role of non-NK
ILC1 in tumorigenesis and although they lack expression of
granzyme and perforin, they may have similar functions to
NK cells in the antitumor response as they share a similar
cytokine secretion signature. Recent studies in models of
inflammatory bowel disease [32, 48] and intestinal infection
with Toxoplasma gondii [9] have demonstrated that cells with
an ILC1 phenotype secrete IFN-𝛾 and TNF-𝛼 and contribute
to the inflammatory response and pathology in response
to IL-12 and IL-15. The antiproliferative and proapoptotic
properties of IFN-𝛾 and TNF-𝛼, produced by activated T
cells and monocyte-macrophages, are well established in
many tumor models. However, whether these cytokines are
secreted by ILC and how thesemight inhibit proliferation and
induction of apoptosis need to be addressed. Interestingly,
Djenidi et al. have shown that ILC1 had an integrin profile
(expression of CD103, integrin alpha E) and a memory-
activated phenotype similar to that observed in tumor-
infiltrating CD8+ T cells, which are tumor-tissue specific and
whose presence correlates with improved early stage survival
in patients with non-small-cell lung cancer (NSCLC) [49].
4.2. ILC2. ILC2 were originally identified in mesenteric
lymph nodes and characterized by their ability to prime
and stimulate Th2 responses. Following stimulation with IL-
25 or IL-33, ILC2 produce IL-5, IL-13 [50, 51], IL-4, IL-6,
IL-9, and amphiregulin which induce Th2 differentiation,
production of antibodies, and class switching [52].The effects
of ILC2 can be mediated through the secretion of pro-Th2
cytokines or by cell-cell interactions via presentation ofMHC
class II-associated antigens to T cells or OX40L stimulation
[53, 54]. IL-5- and IL-13-producing ILC2 are associated with
protective immunity at mucosal surfaces. Clinical studies
suggested that increased numbers of ILC2 in peripheral
blood, and the cytokines they secrete, could contribute to
the immunosuppressive environment maintained by Th2,
myeloid-derived suppressor cells (MDSC), and macrophages
observed in patients with gastric cancer [55, 56]. Ikutani et al.
were amongst the first to show evidence of the role of ILC2 in
cancer. Using a mouse model of lung metastatic melanoma,
ILC2 were specifically shown to produce IL-5 in response to
IL-33 stimulation (Figure 2(a)). Following tumor induction,
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Figure 1: Antitumor activities of group 1 innate lymphoid cells (ILC1). Upon tumor development dendritic cells (DC) are activated and secrete
IL-12, which activates ILC1. ILC1 respond to stimulation secreting IFN-𝛾 and TNF-𝛼, which target and activate different cell types within
the tumor microenvironment that display antitumor activities. These cell types include NK cells that kill tumor cells through mechanisms
involving perforin and granzyme secretion. CD4+ T cells provide costimulation (through cell to cell interactions and secretion of soluble
factors) and priming of CD8+ cytotoxic T cells which display antitumor cytotoxic activities. IFN-𝛾 secreted by ILC1 inhibits the differentiation
of tumor-infiltratingmacrophages intoM2macrophages providing amechanism that prevents secretion of vascular endothelial growth factor
(VGEF) and tumor angiogenesis. Due to cell plasticity ILC3 can differentiate into ILC within the tumor microenvironment and contribute to
the anti- and protumor responses.
administration of rIL-33 induced the development of IL-5-
producing ILC2, which recruited andmaintained eosinophils
that induced tumor cell death and prevented tumor metas-
tasis [57], possibly through an IL-4-dependent mechanism
[58]. Contrary to an observed antitumor effect and highlight-
ing the dual role of ILC in tumor progression, studies with
the 4T1 syngeneic murine model of human triple negative
breast cancer have shown that endogenous IL-33, produced
by tumor cells, was associated with increased frequencies of
TGF𝛽-producing MDSC, regulatory T cells (Treg), and ILC2
that expressed IL-5 and IL-13 (Figure 2(b)). The results sug-
gested that ILC2-derived IL-13 targets and activates MDSC
to express arginase and nitric oxide synthase, contributing to
the establishment of a suppressive environment characterized
by increased numbers of Treg and functionally impaired
NK cells that allow tumor escape and progression [59].
Preliminary evidence suggesting the involvement of IL-33
and Th2-like cells in other forms of cancer was provided
by studies in models of liver disease in which inflammation
and fibrosis can result in cancer. The components of IL-33
signaling axis (IL-33/ST2/IL-1RAcP) are increased in human
and mouse fibrotic livers but not, interestingly, in human
hepatocellular carcinoma [60]. Increased levels of IL-33 were
also found in clinical studies in patients with liver cirrhosis
and mouse models of hepatic fibrosis. In these studies it
was determined that IL-33 secreted by stressed hepatic cells
induced the activation and expansion of ILC2.Activated ILC2
responded by secreting IL-13 that targeted stellate cells, which
contributed to the mechanisms leading to fibrosis [61, 62]. A
recent study highlighting the critical balance that determines
whether ILC2 display pro- or anticancer effects has been
recently published. In studies by Li et al., they have shown
that IL-13 released by IL-33-activated ILC2 promoted prolif-
eration of epithelial cells of the bile ducts or cholangiocytes.
Strikingly, cholangiocyte proliferation induced by exogenous
IL-33, in a model of biliary injury, promoted epithelial repair
(Figure 2(c)). However, the same proliferative effect in mice
with oncogenic priming (constitutively active Akt and Hippo
pathways) induces cholangiocarcinoma and liver metastasis
[62]. These studies suggest that ILC2-activating cytokines
might represent potential targets in the design of anticancer
therapeutic tools.
4.3. ILC3. ILC3 are the group of ILC that have gathered
the most evidence suggesting their role in tumor biology.
Inflammation due to infection and tissue injury confers an
increased risk of cancer and tumorigenesis [63, 64]. In partic-
ular, the association between inflammation and colon cancer
has been documented for more than 30 years in patients with
inflammatory bowel disease (IBD) [65]. IL-17 is an important
cytokine linking both innate and adaptive immune responses
in infection and autoimmunity [66]. Evidence points to its
dual role in both tumorigenesis—inducing angiogenesis [67,
68], tumor evasion, and inhibition of apoptosis—and the
control of antitumor responses that activate and recruit NK
cells, Treg, and neutrophils to the tumor microenvironment.
6 Journal of Immunology Research
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Figure 2: Anti- and protumor activities of group 2 innate lymphoid cells (ILC2). (a) The antitumor activity of ILC2 has been demonstrated
in a model of lung metastatic melanoma. IL-33-activated ILC2 produce IL-5, which induces the recruitment and maintenance of eosinophils
that display antitumorigenic activity. In contrast, ILC2 can also play an important role in tumor progression as shown in models of liver and
breast cancer (b). A study in the 4T1 syngeneic model of breast cancer has shown that IL-33 produced by tumor cells is associated with the
induction of a protumor environment characterized by increased numbers of MDSC and Treg. Contributing to the suppressive environment,
an increased number of ILC2 secrete IL-5/IL-13 and target MDSC, which in turn secrete TGF𝛽 (to activate and maintain Treg) and arginase
(Arg) to inhibit natural killer (NK) cell activity. Under these immunosuppressive conditions, 4T1 tumors develop andmetastasize. (c) Further,
evidence of the dual role of ILC2 in tumor development has been highlighted by studies in models of liver cancer. Cell damage of epithelial
cells lining the bile ducts (cholangiocytes) in the presence of IL-33-activated ILC2 leads to secretion of IL-13, which under normal conditions
is used by epithelial cells to proliferate and induce tissue repair. However, under conditions of oncogenic priming (activation of protumor
signaling pathways) the control of epithelial cells proliferation is lost and leads to tumor development.
Clinical and animal models studies have shown correlations
between the levels of IL-17 and aggressiveness and tumor
progression in gastric, ovarian, breast, and lung carcinomas.
The source of IL-17 in those studies was attributed to Th17,
mast cells, and tumor-associated macrophages (reviewed
in [69]). It is only recently when Kirchberger et al. have
demonstrated that microbe-induced colon cancer is directly
associated with the accumulation of ILC and IL-17 signaling
(Figure 3(a)(i)). Using well-established models of bacteria-
induced colon cancer and antibody-based cell depletion and
cytokine neutralization protocols, the authors concluded that
IL-17 and IL-22 produced by colonic ILC3 contribute to
inflammation and tumor development, with an additional
role for IL-22 to perpetuate the cancerous state by induc-
ing proliferation of epithelial cells in a STAT-3-mediated
mechanism [70]. Whether ILC contribute to recruitment
of Treg, MDSC, and protumor M2 macrophages to induce
an immunosuppressive protumor environment as shown
in mouse models of melanoma and hepatic, cervical, and
prostate cancer remains to be fully established [71, 72]. The
role of IL-22 in color cancer, however, is complex and not
only limited to inducing tumor development, as some studies
Journal of Immunology Research 7
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Figure 3:The role of ILC3 in tumor development. Studies in microbe-induced intestinal cancer have provided evidence of the protumor role
of ILC3. (a)(i) The expression of CXCR6 allows ILC3 to migrate in response to the CXCL13 gradient and localize in gut microenvironments
where they respond to DC-derived IL-23. Upon activation, ILC3 secrete IL-17 and IL-22, which contribute to the inflammatory environment
that supports tumor development by inducing proliferation of epithelial cells in a STAT-3-mediated mechanism.The control of IL-22 activity
by a soluble receptor, IL-22BP, is important to maintain a fine balance that dictates proliferation and tissue repair or tumor development.
Highlighting the importance of crosstalk between ILC and other immune cells, gutmacrophages (a)(ii) activated bymicrobial signals produce
the proinflammatory cytokine IL-1, which targets and induces ROR𝛾t+ ILC to secrete GM-CSF required to maintain Treg and macrophages.
The action of these three cell types creates a tolerant environment that results in tumor progression. Another potential mechanism that might
operate in cancer involves Ly6hi monocytes (a)(iii), which produce TNF-𝛼 following stimulation by microbial signals. The proinflammatory
monocytes increase the frequency of IL-17-producing ILC3 and as part of the functional circuit IL-17 acts upon monocytes to increase
their microbicidal activity. It would be interesting to evaluate whether this functional circuit results in increased tumoricidal activity by
inflammatory monocytes. In subcutaneous melanoma, tumor-derived IL-12 activates NKp46+LTi, which induce the tumor microvasculature
to express increased levels of ICAM and VCAM. The increased expression of these adhesion molecules allows the infiltration of CD4+ and
CD8+, which mediate tumor suppression. Panel (a)(i) diagram is based on [35].
have shown that IL-22 can display antitumor effects. The
control of IL-22 activity is regulated by IL-22 binding pro-
tein (IL-22BP), an endogenous neutralizing soluble receptor
(Figure 3(a)(i)). Using a model of colon cancer in mice
deficient for IL-22BP, Huber et al. demonstrated that IL-22
has an important role in the homeostatic colonic epithelial
cell repair. However, in the absence of IL-22BP, the control of
the activity of IL-22 by this soluble IL-22 receptor is lost and
its protumorigenic activity is triggered [73]. Although, in this
study, the source of IL-22 was not attributed to ILC, given the
recruitment and presence of these cells in the inflammatory
tissue environment, it is likely that they might play a role.
In a different model of IBD, the IL-23/IL-17 signaling axis
has been reported to operate in the development of mouse
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gut adenocarcinomas. In the absence of carcinogens or
bacterial infection, transgene expression of IL-23 activated
IL-23R+ILC, which responded by producing IL-17, IFN-𝛾,
and IL-22 which contributed to tumor development [74].
These studies suggest that IL-23, IL-17, and IL-22 could be
considered as novel therapeutic targets. Interestingly, IL-
22-independent crosstalk between ILC3, macrophages, and
intestinal microbes has been recently described. Mortha et al.
have shown that gutmacrophages respond tomicrobe signals
by producing IL-1 (Figure 3(a)(ii)). This proinflammatory
cytokine induces ROR𝛾t+ILC to secrete GM-CSF, which is
required tomaintain the tolerancemediated bymacrophages,
DC, and Treg [75]. This study showed that deficiency of GM-
CSF led to reduced numbers of Treg, thus suggesting that
targeting the ability of ILC3 to produce GM-CSF could be
used as a therapy in cancers where Treg have been described
to be increased [76]. Another interestingmechanism of toler-
ance induction involving ILC3 yet independent of cytokines
IL-17, IL22, or IL-23 has been recently described. Hepworth
et al. [77] demonstrated that ROR𝛾t+ILC3 express MHC-II
molecules and present antigens in the absence of costimula-
tory molecules which allows them to limit microbial-specific
CD4+ T cell responses which if uncontrolled would cause
intestinal inflammation [77]. Whether this is a mechanism
that operates in the tumor microenvironment and enables
ILC to present tumor antigens and thereby inhibit tumor-
specific antigen responses by cytotoxic and effector T cells
has not been evaluated. These studies highlight the emerging
view on the critical importance of the interactions between
resident commensal bacteria and cells of the immune system
that maintain gut homeostasis. There are contrasting reports
showing, on the one hand, that bacteria are able to promote
antitumor responses and, on the other hand, that crosstalk
between bacteria and ILC leads to chronic inflammation and
cancer development.These observations have clinical impor-
tance as many patients with cancer are treated with drugs
that might compromise the integrity of intestinal cells, and
whether this can have an effect on shifting a balance towards
pro- or antitumor responses is something that merits careful
consideration [78]. The recently described crosstalk between
ILC3 andmonocytes highlights another potentialmechanism
that might operate in cancer. Xiong et al. have shown in
a model of lung infection with Klebsiella pneumoniae that
bacterial infection induces the recruitment of proinflamma-
tory Ly6Chi monocytes, which produce TNF and increase
the frequency of IL-17-producing cells (Figure 3(a)(iii)). IL-
17 released by ILC3 acts upon recruited monocytes and these
cells increase their microbicidal properties and manage to
clear off the infecting bacteria [79]. It is very tempting to sug-
gest that such a mechanism with activated monocytes could
target tumor cells in a TNF-mediated mechanism. Further
to the well-characterized IL-12-dependent cytotoxic activity
by Th1 and NK cells, studies with IL-12-deficient mice and
mice lacking mature B and T cells (RAG-2 knock-out) have
provided clear evidence that IL-12 is an important effector
cytokine in the response against melanoma [80, 81]. These
results provided a basis to suggest that ILC are involved in
the antitumor function of IL-12. Indeed, Eisenring et al. have
described an alternative tumor suppression mechanism that
depends on the activation of NCR-expressing NKp46+LTi, a
member of ILC3. Using models of subcutaneous melanoma,
IL-12 secreted by tumor cells activated NKp46+LTi and
these cells induced the tumor microvasculature to express
increased levels of ICAM and VCAM. The expression of
these two adhesion molecules then allowed the infiltration
of CD4+ and CD8+, which mediate the tumor suppres-
sion (Figure 3(b)). Interestingly, IL-12 treatment induced
NKp46+LTi to secrete IFN-𝛾 and LT cytokines, which have
well-characterized antitumor and proapoptotic functions.
However, the observation that IL-12-mediated tumor rejec-
tion operated in IFN-𝛾−, IFN-𝛾R−, or perforin-deficient mice
suggests that in this model NKp46+LTi do not contribute
to the antitumor activity of other innate (NK) or adaptive
(CD4+ and CD8+ T) cells in the TME [82]. The role of LTi-
like cells has also been highlighted in studies with CCL21-
producing melanoma cells. Along with the formation of
lymphoid tissue, tumor-derived CCL21 induced the recruit-
ment of LTi-like cells to the TME. Whether the induction
of lymphoid-like stroma tissue facilitates immune escape
or tolerance has not been fully established [83]. In our
own recent studies in patients with triple negative breast
cancer (TNBC), we have found evidence suggesting that
ROR𝛾t+ILC3 might contribute to tumor metastasis through
a differentmechanism. First, ROR𝛾t+ILC3 localize within the
primary tumor and an increased number of these cells are
associated with tumor migration into lymphatics and subse-
quent lymphnode (LN)metastasis. Using the 4T1.2 syngeneic
model of breast cancer we showed that ILC3 recruitment
to primary tumors is CCL21-dependent. Once within the
tumors, ILC3 stimulate stromal cells to produce CXCL13,
which feeds back to promote the production of LT and
receptor activator of nuclear factor kappa-B ligand (RANK-
L) to promote lymphangiogenesis and enhance tumor cell
motility [84]. The identification of ILC3 within the human
breast cancer microenvironment is a significant advance for
understanding tumor-stromal interactions and their effect on
malignant phenotypes in cancer. Analysis of a cohort of 234
breast cancer patient samples showed a correlation of tumors
with aggressive invasive properties and a signature of genes
expressed by ILC3, enriched for CXCL13, CCL19, CCL21,
and the receptors CXCR5 and CCR7 [84]. These findings
have potential clinical relevance because they might relate
to lymphatic invasion leading to lymph node metastases,
a feature routinely assessed by pathologists and considered
as poor prognostic factor for breast cancer patients. These
results suggest, as seen in other studies, that ILC3 might
have different roles in tumor progression depending on the
type of tumor and the specific characteristics of the TME.
An interesting mechanism through which ILCmay influence
tumor development is by their role in the formation of
tertiary lymphoid structures (TLS). It has been shown that the
proinflammatory features of the TME lead to the activation
of chemokine signaling pathways and the recruitment of
immune cells that contribute to the formation of TLS [85].
TLS are ectopic and highly organized lymphoid formations
that develop in inflamed and infected tissues or within
or adjacent to primary tumors. These formations present
well-defined T and B cell zones, high endothelial venules
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(HEV), mature DC, germinal centre reactions, and B cell
class switch in the B cell follicles, suggesting the generation of
adaptive immune responses [86]. These lymphoid aggregates
are also characterized by the expression of chemokines
(CCL19, CCL21, CXCL10, CXCL12, and CXCL13), adhesion
molecules (ICAM-2, ICAM-3, VCAM-1, and MAdCAM-1),
and integrins (alphaL, alpha4, and alphaD) [87], which not
only attract effector immune cells such as Treg, DC, na¨ıve B
cells, andT follicular helper (TFH) cells but also determine the
architecture and cell segregation in specific compartments.
The composition of TLS might be different depending on the
tumor type and a growing number of clinical studies suggest
that TLS and associated biomarkers correlate with clinical
outcome and prognostic value [88]. Studies of patients with
melanoma, breast [89], colorectal, lung, pancreas [90], or
renal cell carcinomas have shown that the presence of TLS is
of positive prognostic value. However, two different studies
in patients with breast and renal cell carcinomas have also
shown that the presence of TLS has a negative prognostic
value (an extensive revision of the clinical studies and trials
are reviewed in [86, 91]). Detailed analyses have found that
particular cell types within the TLS confer the prognostic
value; for instance, CD8+ T cells and antibody-producing-
plasma cells in ovarian cancer [92] and DC in primary
lung tumors [93] confer a positive prognostic value. On the
other hand, Joshi et al. have recently shown that tumor-
infiltrating Treg in a mouse model of lung adenocarcinoma
are increased and found at the tumor margins in tertiary
lymphoid structures. At these sites, Treg actively restrain
effector T cells [94]. These results, elevated numbers of
Treg, correlate with the adverse clinical outcome (poor
survival) in patients with breast cancer [95]. In a striking
study, Finkin et al. have used a model of hepatocellular
carcinoma (HCC) with mice constitutively expressing the
active form of IKK-B in hepatocytes to activate the NF-𝜅B
pathway. They reported the presence of small clusters of
hepatocytes expressing markers of tumor progenitor cells
within TLS formed in nontumor sites of the inflamed liver.
These clusters progressively coalesced and egressed from the
TLS to grow as HCC in all IKK-B-expressing livers. These
results suggest that TLS serve as niches supporting tumor
cells growth and contribute to recurrence in HCC [96].
Despite the strong correlation between clinical or prognostic
value and the presence of TLS in different types of cancer,
it is unclear which factors (intrinsic or extrinsic) contribute
to their development. Studies from the rheumatology field
have suggested a role for ILC in the formation of TLS. Noort
et al. have recently shown that TLS within the synovial
tissue of some patients with rheumatoid arthritis contain low
numbers of CD3−RORC+ ILC3 which might play a role in
TLS formation through a mechanism involving the release of
LT𝛽 and the expansion of follicular DC [97]. Interestingly,
in the cancer setting, Carrega et al. have recently reported
the presence of NCR+ILC3 at the edge of tumor-associated
TLS in NSCLC. Increased number of these cells in early stage
tumors correlated with the density of intratumoral TLS and
predicted favorable clinical outcomes [98]. Further analyses
are required to evaluate the role of ILC3 on TLS formation
and function in other types of cancer. From the studies
mentioned above, it is clear that identifying the mechanisms
and cellular components underlying TLS formation will be
helpful to understand the pro- and antitumor responses
within the tumor microenvironment. This knowledge will
be helpful to develop new therapies to promote or inhibit
TLS formation. In fact, different drugs and antagonist of
the LT𝛼/𝛽, RANK/RANK-L, and ICOS/ICOS-L signaling
pathways are being developed and tested for their potential
to manipulate TLS formation (reviewed in [91]). Thus, the
paradoxical role of ILC3 in both host protective and tumor-
promoting immunosuppressive effects can be associated with
the reported functional plasticity that allows these cells
to respond to changes in the tumor microenvironment
accordingly (reviewed in [6]). Whether ILC display pro- or
antitumor activities seems to depend on the type of tumor
and stage of development and on the complex network of
fine-tuned incoming signals that control cell-cell interactions
in themicroenvironment. It is likely that the ability to control
or influence those interactions will be important for the
development of new therapeutic tools to fight cancer. Recent
encouraging studies with chemical inhibitors of ROR𝛾t-
mediated transcription (such as GSK805) have revealed a
transient and specific targeting/inhibition tool for ROR𝛾t+
cells. In a recent study of a model of intestinal infection
with bacteria, administration of GSK805 reduced cytokine
production by Th17, but not ILC3, thus preserving innate
immunity. This treatment resulted in a therapeutic response
as reduced activity of Th17, but not ILC3, contributed to
the control of inflammation in their infection model [99].
Given the nonredundant functions of cytokines produced by
T cells and ILC, this cell-specific and transient inhibition of
ROR𝛾t+ cells might have applications in models of cancer
where manipulating and enhancing the antitumor functions
of ILC over the proinflammatory functions of Th17 might
be beneficial and important to control tumor development.
Details on how these cytokines, chemokines, and growth
factors allow the cell-cell interactions that maintain the
homeostatic balance are currently being explored and will be
essential for the development of new therapeutic tools against
cancer. In the next sectionwewill discuss imaging approaches
to analyze the crosstalk between ILC and other innate and
adaptive immune cells.
5. Imaging Strategies to Study the
Crosstalk and Interactions between
ILC and Other Immune Cells
Immunohistochemistry (IHC), immunofluorescence, and
flow cytometry methodologies are fundamental tools that
have contributed to the identification and our knowledge
of the different ILC subsets. In some studies and using
IHC techniques, ILC1 have been identified with markers
NKp44+, CD103+, and CD3− [48] and ILC3 using Ror𝛾t+IL-
7RB+CD11c− [100] or CD3−CD127+CD117+ROR𝛾t+ [101].
With the use of many different markers and multicolor
cytometric analyses, it has been possible to study and
determine the presence and changes in ILC populations
in normal, disease, and inflammatory settings. However,
understanding the roles of ILC in the control of immune
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responses requires a refined knowledge of the crosstalk and
interactions between ILC and other innate and adaptive
immune cells. This has been approached through the use
of novel imaging techniques using fluorescent probes. Using
ILC3 as an example, here we describe some approaches that
can be used to examine the role of ILC in the ex vivo and in
vivo settings.
A major complication arising when looking at a subset of
cells, such as the ILC, is the necessity to define that subset with
a range of different markers. The current series of markers
and phenotype accepted for identifying ILC3 require four
(five including a nuclear stain) separate fluorophores when
imaging tissue to identify the one cell type. If ILC3 are
to be imaged along with other cells of interest, the use of
serial sections is required, labeling a certain cell type per
section and overlaying the images. Alternatively, a multiplex
of 6 or 7 fluorescent probes can be used to identify two
different cell types on a single slide and imaging on a
standard commercial confocal microscope. Using multiple
fluorophores in a single slide is generally better accepted
as it avoids any slight alterations between sections and the
inherent difficulty in obtaining good quality sequentially
cut sections. With using such a high number of fluorescent
proteins on the same slide, it is common to find spectral
bleed-through and cross-excitation between the detected
channels. Fluorophore selection including fluorophores with
large stokes shift, such as the Brilliant Violet and Pacific
Blue/Green/Orange, and the use of quantum dots [102] allow
multiplexing on a single excitation laser. This approach,
combined with carefully customized microscope configura-
tion, means it is possible to avoid spectral bleed-through
altogether [103]. However, in the cases where it is unavoid-
able, postacquisition correction algorithms can be utilized to
correct for unwanted fluorescent emission crosstalk (spectral
overlap) by deconvolution/unmixing [104] to remove any
remaining overlaps between the fluorophores of the detected
channels [105]. Multicolor confocal microscopy provides
high-resolution tissue imaging, allowing the labeling of
different cell types that require several markers to identify.
This provides key localization information in fixed tissue at
a particular time point and as such is extremely useful in
indicating possible cellular interactions based on the relative
cell-cell proximity, which can be further investigated using
time-lapse microscopy or other means. A drawback of using
confocal microscopy as an approach to imaging ILC3 is
the lack of temporal information. Relatively little is known
regarding the role these cells play in different scenarios;
therefore, the ability to track where these cells migrate and
the cells they interact with is fundamental to deciphering
their role and function.Multiphotonmicroscopy (also known
as 2-photon microscopy) allows the imaging of fluorescently
labeled cells deep within tissue in an in vivo setting, visu-
alizing cell behavior in the natural environment. Kinetic
information such as cell velocity, track length, meandering
index, and displacement can reveal valuable information
regarding immune cells activity [106, 107] and the ability
to image and track the interactions between different cell
subsets is fundamental to further elucidate the roles ILC3may
play in inhibiting particular signaling or receptor pathways.
Current commercial multiphoton systems typically have the
capacity for 2 to 4 fluorescent probes to be imaged at a
time, and using the same multifluorescent labeling as used
in confocal microscope is impractical. In this situation, the
preferable method is to isolate ILC3 using flow cytometry
based cell sorting with the markers for ILC3 (CD3, CD127,
CD117, and NKp46), followed by fluorescent labeling of this
population using cell tracker dyes [108]. These labeled cells
can then be injected intravenously into the target animal and
imaged 18–72 hours later, allowing for the cells to migrate
to their respective homing tissues [108, 109]. This method
allows for the imaging of ILC3 using a single fluorescent
channel, leaving the rest for additional labeled cells of interest.
As multiphoton microscopy is primarily used for intravital
imaging, several approaches could be used to facilitate the
imaging of ILC3. The activity of ILC3 within the lymph node
could be imaged in a direct manner by surgically exposing
the inguinal lymph node [110]. While this approach allows
for controllable intravital imaging, it is a terminal proce-
dure and specific experimental time points must be chosen
when imaging. This approach could be applied to models
of breast cancer with direct exposure and imaging of the
draining inguinal lymph node and the primary tumor [111].
Furthermore, in the same tumor model, the use of surgically
implanted windows can allow for longitudinal imaging of
these organs, allowing repeated imaging of the same tissue
throughout tumor development, with or without experimen-
tal intervention. A small abdominal window implanted over
the inguinal lymph node allows the inguinal lymph node to
be reexposed several times for imaging [112]. ILC3 can also
be imaged deep within tumors via a mammary window that
is inserted in the skin over the lower mammary gland region.
Breast cancer cell lines can then be injected/implanted and
allowed to grow up into the recess created by the window,
therefore allowing a surgery free method of imaging ILC3
behavior over the development of the tumor [111, 113, 114].
The use of this window method can be extended to imaging
ILC3 in the lung using a technique developed by Looney et
al. [115] which, although terminal, can allow the studying of
ILC3 and other target cells in a fully functional lung from
chronic obstructive pulmonary disease [116] and lung cancer
[98]. Taking advantage of current photo-switchable mouse
models provides another tool to examine ILC3 function. In
these mice, exposure to ultraviolet light induces changes in
fluorescence on the reporter cells [117]. Using this, organs or
tissues of interest can be activated using a UV light source,
either through surgical exposure or using the aforementioned
window systems, and the migration of cells from this tissue
was tracked, for instance, as has been shown between intes-
tine and mesenteric lymph nodes [36]. This same approach
could be applied to a variety of tumor models to further
unveil ILC3migration properties and the elements that affect
them.
6. Conclusions
Interest and attention on ILC has increased in recent years
and a great deal of information has been gathered. The
discovery of this family of innate immune cells, the definition
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of their phenotypes, and their classification into different
subgroups based on their differentiation requirements and
biological functions represent important achievements in
biomedical research.The description of intricate interactions
in different tissues and organs, beyond the gut, with other
innate and adaptive immune cells in homeostasis or during
different types of infection, inflammatory diseases, and can-
cer partially highlights the functional importance of these
cells. The challenge for future research is to fully understand
and decipher the complex and specific contributions of
each type of ILC to the control and regulation of immune
responses. In particular, further studies on dissecting the
detailed nature and implications of the reported plasticity
will be required. In the specific case of cancer, observations
from the clinic and studies in a variety of animal models
have shown opposing abilities of ILC to either promote or
repress tumor growth. A better understanding of the precise
roles of ILC cell types in tumorigenesis or control will allow
understanding of the potential value of manipulation of
their functions to develop new interventions and therapeutic
strategies.
Additional Points
Review Search Strategy.This is a narrative review.We searched
PUBMED for original articles focusing on innate lymphoid
cells and cancer published in the last 10 years, from 2006
to 2016. Search terms included “Group 1, 2, and 3 Innate
lymphoid cells and tumor”, “ILC1, 2, 3 and cancer”, and
“Innate lymphoid cells and tumor microenvironment”. All
papers identified were English-language, full-text papers. We
also searched the reference lists of identified articles for
further papers.
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